386 results about "First myocardial infarction" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The embodiment of the invention provides a myocardial infarction risk prediction model training method and related equipment, and belongs to the technical field of machine learning. The myocardial infarction risk prediction model training method comprises the steps of obtaining initial training data, performing multiple times of characteristic variable screening on the initial training data through a single factor analysis method and an LASSO regression method to obtain training case data, and inputting the training case data into a BP neural network model for nonlinear data processing to obtain the prediction probability of myocardial infarction occurrence. And performing parameter optimization on the BP neural network model according to the prediction probability and the real occurrence probability to obtain a myocardial infarction risk prediction model. According to the embodiment of the invention, nonlinear processing can be carried out on high-dimensional or multivariable training case data through the BP neural network model, and the processing capability of complex data and the accuracy and stability of myocardial infarction risk prediction are improved.

The invention discloses an acute myocardial infarction cardiovascular risk prediction method based on artificial intelligence. The method comprises the following steps: collecting clinical data of a patient and integrating the clinical data into an initial data set; performing cleaning, missing value processing and classification processing on the data initial set, and constructing a standardized feature data set; a competition risk outcome type is defined according to clinical follow-up visit data of the patient, and competition risk label data is constructed; an improved DeepHit model is established; training and cross validation are carried out by using the standardized feature data set and the competitive risk label data, and a training completion model is determined; and predicting the individual competition risk probability of the patient, and generating a risk level and an early warning prompt. According to the invention, individualized dynamic risk prediction is realized, and clinical diagnosis and treatment decision reliability is enhanced.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention discloses application of a protein marker CA1 in preparation of a reagent or a kit for early diagnosis of myocardial infarction, and is characterized in that the protein marker is CA1 and a GH1 and CA1 protein combination, and also provides application of the related protein marker in preparation of the reagent or the kit for early diagnosis of myocardial infarction. The kit has the advantages that early-stage AMI diagnosis can be conveniently and quickly realized on the molecular level, the detection efficiency is high, the sensitivity is high, the pertinence is strong, and early-stage discovery and timely treatment of AMI patients are facilitated.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The invention provides a self-adaptive multifunctional hydrogel system for cardiac microenvironment regulation after myocardial infarction as well as a preparation method and application of the self-adaptive multifunctional hydrogel system, and belongs to the technical field of biomedical materials. The hydrogel system is hydrogel prepared by taking a micromolecular cross-linking agent, a polymer matrix and drug-loaded microspheres as raw materials. The hydrogel can realize staged response drug release in oxidative stress, inflammation and fibrosis microenvironments after myocardial infarction, has good injectability and self-healing property, and has the functions of ROS removal, nitric oxide release and the like. The invention provides a new strategy for tissue repair after myocardial infarction with multi-channel collaboration and accurate pathological response control.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention relates to the technical field of data processing, in particular to a system for predicting the death risk of a myocardial infarction patient through an artificial intelligence algorithm. Comprising a multi-modal data acquisition module, a data quality perception and real-time complementation module, an unsteady robust feature engineering module, an AIMI-Core prediction engine, a pre-hospital-intra-hospital resource linkage decision module, a digital twin simulation and Pareto optimal scheme generation module and a scheme execution and intervention catheter chamber reverse control module. And the end feedback and dual-channel closed-loop optimization module, wherein all the modules are in synchronous hard-wired connection with an IEEE 1588-2019 PTP clock through a dual-ring redundant Ethernet. The modules are cascaded to realize a prediction-decision-execution-feedback closed loop.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention discloses a biomarker combination for predicting PCI postoperative LVR of an STEMI patient and application of the biomarker combination, and belongs to the technical field of biology. The research discovers that in a left ventricular remodeling (LVR) group and a non-left ventricular remodeling group after percutaneous coronary intervention (PCI) of a patient suffering from acute ST segment elevation type myocardial infarction (STEMI), a left ventricular endocardial lower myocardial overall longitudinal strain (GLS internal) value, a lung B-line integral, a serum sFRP5 level and Apelin-13 show significant differences. Through combined prediction analysis, it is found that the GLS internal value, the lung B-line integral, the serum sFRP5 and the Apelin-13 have excellent prediction performance on whether the LVR occurs after the PCI operation of the STEMI patient or not, high-risk groups, suffering from the LVR after the PCI operation, of the STEMI patient can be accurately and efficiently recognized, intervention is conducted as soon as possible, and the life quality of the patient is expected to be improved.

The application relates to the field of myocardial ischemia-reperfusion injury drugs, and discloses application of Gualou Xiebai Baijiu decoction in preparation of myocardial ischemia-reperfusion injury drugs. The myocardial ischemia-reperfusion injury drugs inhibit the GSK-3beta / Drp1-mediated mitochondrial fission pathway by targeting Akt protein, maintain the dynamic balance of mitochondrial dynamics, and play a myocardial protection role. The drugs can promote Akt phosphorylation activation, inhibit GSK-3beta activity, down-regulate Drp1 protein Ser616 site phosphorylation, up-regulate Ser637 site phosphorylation, reduce Drp1 translocation and aggregation to the outer membrane of mitochondria, and simultaneously up-regulate the expression of mitochondrial fusion proteins Mfn1 and Mfn2. The drugs can maintain the structural integrity of mitochondria, improve the mitochondrial membrane potential and ATP content, improve myocardial cell energy metabolism, regulate the expression of apoptosis-related proteins to inhibit myocardial cell apoptosis, improve the cardiac systolic function after ischemia-reperfusion, reduce the myocardial infarction area, reduce the serum myocardial injury marker level, and regulate the oxidative stress state.

The application relates to the technical field of biological medicine, and discloses a drug composition containing nuclear autoantigen sperm protein for promoting myocardial regeneration and repair and application, which comprises an NASP gene; the nucleotide sequence of the NASP gene is shown as SEQ ID NO:1, and the amino acid sequence encoded by the NASP gene is shown as SEQ ID NO:2. The drug composition can promote the number of myocardial cells, repair the necrotic myocardium, and thus improve acute myocardial infarction at the gene level.

The invention discloses a digital portable myocardial infarction early analysis and early warning device, and belongs to the technical field of medical monitoring equipment. The device comprises a physical sign acquisition unit, a data processing unit, an early warning control unit, a positioning unit, a power supply unit and a data interaction unit. Physiological sign signals and subjective feelings of a user are acquired through the sign acquisition unit; the data processing unit analyzes the data by using a built-in algorithm, and compares the data with a health baseline to identify a special atypical risk signal in the early stage of myocardial infarction; the early warning control unit has an active and passive dual early warning mode, and can automatically call for emergency treatment and report the position by using the positioning unit when the active early warning is invalid; and the data interaction unit supports linkage with an external medical system. The myocardial infarction risk early warning system realizes household, instant and intelligent early warning of myocardial infarction risks, is especially good at capturing subtle symptoms which are easy to ignore, and effectively solves the problems that a traditional detection mode is lagged, is not portable and cannot perform continuous monitoring.

Provided herein are epicardium-derived paracrine factors for repairing heart tissue. In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors, such as hypoglycosylated follicular- stimulating hormone-like 1 (FSTL1), for treating and repairing damage to heart tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or heart growth defects, and methods of using the same.

The invention discloses a real-time myocardial infarction risk prediction data processing system based on edge calculation, and relates to the technical field of medical data processing. The system comprises a prediction data acquisition-quantification module, a risk prediction data intelligent optimization module, a drift rate data acquisition-quantification module and a drift correction intelligent optimization module. According to the method, the accuracy of myocardial infarction risk prediction data is obtained through quantification of obtained risk prediction data, whether intelligent optimization of the myocardial infarction risk prediction data is executed or not is judged, dynamic drift rate data in an edge-cloud collaborative management link is obtained through quantification of dynamic drift rate data to obtain the dynamic drift rate of an edge model, and whether intelligent optimization of dynamic drift correction is executed or not is judged. The accuracy of real-time myocardial infarction risk prediction data processing is improved, and the problem that in the prior art, the accuracy of real-time myocardial infarction risk prediction data processing is low is solved.

A new blood assay is provided which identifies patients who develop hemorrhage after revascularization therapy based on temporal kinetics of free serum iron levels. This approach overcomes the limitations of gold-standard clinical practice of performing cardiac magnetic resonance imaging, as the latter is not always accessible due to poor availability and a high cost. The blood assay can be a new diagnostic approach to broadly permit classification of myocardial infarction based on hemorrhage status, and to allow for suitable management of hemorrhagic patients, who would otherwise carry a significant risk for heart failure and sudden death.

An object of the present invention is to provide a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure using Htra3 as a therapeutic target. According to the present invention, there is provided a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure containing at least one of (a) serine protease HtrA3, (b) a nucleic acid encoding HtrA3, (c) an expression vector containing a nucleic acid encoding HtrA3, (d) a cell transformed with the nucleic acid or the expression vector, and (e) an antibody that binds to serine protease HtrA3.

1. Name of the product in this design: Percutaneous ventricular assist device. 2. Purpose of this design: for use in medical and health care, for emergency support in cases of acute myocardial infarction, cardiogenic shock, high-risk PCI, etc. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

The application discloses application of a genetic lineage tracing mouse model in regulation of myocardial cell transformation into osteoblasts, and belongs to the technical field of biotechnology.The tracing mouse model is induced to have myocardial calcification through high-dose steroids or myocardial infarction operation, the tracing mouse model expresses a label protein in myocardial cells of mammals, and the label protein expression in the myocardial cells is realized through a Cre / loxP system.The genetic lineage tracing mouse model provided by the application can be used for detecting myocardial cell transformation into osteoblasts, and can also be used for developing or screening drugs capable of preventing myocardial calcification or preparing products for developing or screening the drugs capable of preventing myocardial calcification.

The invention provides a nano-enzyme hydrogel delivery system and application of the nano-enzyme hydrogel delivery system in myocardial infarction repair, and particularly provides COF nano-particles, hydrogel wrapping the COF nano-particles and application of the hydrogel. The COF nano-particles are obtained by reacting precursor raw materials including 4, 4 ', 4' '-(1, 3, 5-triazine-2, 4, 6-triyl) triphenylamine (TTA) and 2, 5-dimethoxy terephthalaldehyde (DMTP) and then calcining, and the hydrogel wrapping the COF nano-particles comprises a hydrogel skeleton formed by mixing and cross-linking a dextran hydrogel monomer and a chitosan hydrogel monomer and the COF nano-particles wrapped in the hydrogel skeleton.

The invention relates to the technical field of electrocardiosignal quality evaluation, and discloses an electrocardiosignal quality evaluation method based on an unsupervised cascade adaptive network, which comprises the following steps: S1, preprocessing an obtained original electrocardiosignal: removing power frequency interference through adaptive notch filtering, removing high-frequency myoelectricity noise through soft threshold wavelet filtering, and obtaining a pre-processed electrocardiosignal; keeping a potential pathological characteristic waveform in a filtering process to obtain a preprocessed electrocardiosignal; s2, unsupervised multi-modal feature extraction: an unsupervised feature extraction network is constructed based on an auto-encoder; a normal electrocardiosignal distribution rule is automatically learned through an auto-encoder, so that the dependence on labeling resources of professional doctors is reduced; meanwhile, by means of a two-stage self-adaptive evaluation network, significant noise is filtered first, then pathological signals and noise are accurately distinguished, it is effectively avoided that abnormal waveforms caused by diseases such as myocardial infarction and atrial fibrillation are misjudged as noise, the retention rate of the pathological signals is remarkably increased, and more complete effective data support is provided for clinical diagnosis.

The present disclosure provides devices, systems incorporating the devices, methods for manufacturing the devices, and methods of using the devices for carrying out assays, such as chemical and / or biological assays. The systems include a wearable device including a biosensor having a plurality of electrodes. A functionalized coating is coupled to an electrode of the biosensor. A controller may sense an electrochemical response of the biosensor, and determine whether a health-related biomarker is present based on the electrochemical response. The functionalized coating may include a sulfonated block copolymer such as sulfonated styrene-isobutylene-styrene (SIBS). The health-related biomarker may include cardiac troponin I (cTnI).